// App-Quantinova.ai

FR-OR24 : Efficacy and Safety of Difelikefalin for Moderate-to-Severe CKD–Associated Pruritus: A Global Phase 3 Study in Hemodialysis Patients (KALM-2)

Researchers

Presenter

  • Wooldridge ThomasD

Principal Investigators

  • Mccafferty Kieran

  • Schoemig Michael

  • Csiky Botond Szabolcs

  • Zwiech Rafal

  • Wen Warren

  • Munera Catherine

  • Menzaghi Frederique

Medical Centers

  • Nephrology & Hypertension Associates, LTD, Tupelo, Mississippi, United States

  • Paediatrics, Royal London Hospital Barts Health NHS Trust, London,United Kingdom

  • Dialysezentrum Heilbronn Heilbronn Germany

  • FMC Szatellita Dialysis Center Pecs Pecs Hungary

  • Norbert Barlicki Memorial Teaching Hospital No. 1 of the Medical University of Lodz Lodz Poland

  • Cara Therapeutics, Inc., Stamford, Connecticut, United States

Locations

  • United States

  • United Kingdom

  • Germany

  • Hungary

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • Uraemic pruritus

Biomarkers

  • N/A

Drug/Treatment

  • Difelikefalin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved